HDAC1-IN-17
HDAC1-IN-17 is a selective HDAC1 inhibitor (IC50: HDAC1 3.7 nM; HDAC2 333.7 nM; HDAC6 33.4 nM; HDAC8 514.9 nM). HDAC1-IN-17 upregulates ACSL4 by increasing histone acetylation at the ACSL4 promoter and enhancer, induces lipid peroxidation, Ferroptosis and immunogenic cell death (accompanied by calreticulin exposure and release of damage-associated molecular patterns), and promotes systemic antitumor immunity. HDAC1-IN-17 inhibits tumor growth in esophageal squamous cell carcinoma xenograft and allograft models.
For research use only. We do not sell to patients.
- Formula: C24H20BrN3O2
- Molecular Weight:462.34
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
IC50 & Target
[1]|
HDAC1 3.7 nM (IC50) |
HDAC2 333.7 nM (IC50) |
HDAC6 33.4 nM (IC50) |
HDAC8 514.9 nM (IC50) |
ACSL4 |
Cellular Effect
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| SW1990 | IC50 |
10.47 μM
|
Cytotoxicity against human SW-1990 cells assessed as viability reduction after 48 hrs incubation by CCK-8 assay.
Cytotoxicity against human SW-1990 cells assessed as viability reduction after 48 hrs incubation by CCK-8 assay.
|
42917909 |
| BXPC-3 | IC50 |
3.63 μM
|
Cytotoxicity against human BxPC-3 cells assessed as viability reduction after 48 hrs incubation by CCK-8 assay.
Cytotoxicity against human BxPC-3 cells assessed as viability reduction after 48 hrs incubation by CCK-8 assay.
|
42917909 |
| KYSE-520 cell line | IC50 |
3.15 μM
|
Cytotoxicity against human KYSE520 cells assessed as viability reduction after 48 hrs incubation by CCK-8 assay.
Cytotoxicity against human KYSE520 cells assessed as viability reduction after 48 hrs incubation by CCK-8 assay.
|
42917909 |
| A549 | IC50 |
4.72 μM
|
Cytotoxicity against human A549 cells assessed as viability reduction after 48 hrs incubation by CCK-8 assay.
Cytotoxicity against human A549 cells assessed as viability reduction after 48 hrs incubation by CCK-8 assay.
|
42917909 |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:KYSE520 cells
-
Concentration:5 µM
-
Incubation Time:24 h
-
Result:Induced dose-dependent apoptosis, with nearly 30% apoptotic cells at 5 µM.
-
Cell Line:AKR murine ESCC cells
-
Concentration:5 µM; 2 µM (AA)
-
Incubation Time:24 h
-
Result:Increased surface exposure of CRT and promoted HMGB1 release from the nucleus into the cytoplasm; AA co-application further potentiated both DAMP signals.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:BALB/c nude (female, 6 weeks old)[1]
-
Dosage:20 mg/kg; 40 mg/kg
-
Administration:i.p.; once daily; 19 days
-
Result:Tumor growth inhibition (TGI) was 52.5% at 20 mg/kg and 64.6% at 40 mg/kg.
-
Animal Model:C57BL/6N (female, 6 weeks old)[1]
-
Dosage:40 mg/kg (alone); 40 mg/kg plus arachidonic acid 10 mg/kg (combination)
-
Administration:i.p.; once daily; 15 days
-
Result:TGI was 63.4% alone and 79.1% plus arachidonic acid.
Tumor-draining lymph node mature DCs were 36.6% alone and 42.9% with arachidonic acid.
Splenic CD4+ T cells were 12.5% alone and 20.3% with arachidonic acid; splenic CD8+ T cells were 8.51% and 14.5%, respectively.
Intratumoral CD4+ T cells were 12.4% alone and 17.6% with arachidonic acid; intratumoral CD8+ T cells were 14.5% and 19.8%, respectively.
- Cell Cytotoxicity Assay
- Mammalian live/dead viability and cytotoxicity staining
- Patient-Derived Xenograft (PDX)
- Apoptosis Solutions
- Patient-Derived Orthotopic Xenograft (PDOX)
- Splenic/Portal-Vein Liver Metastasis Xenograft
- Ferroptosis Solutions
- Subcutaneous Cell-Line-Derived Xenograft
- Research Protocol for Cancer Immunology
- Orthotopic Cell-Line Xenograft
- Intraperitoneal/Peritoneal Dissemination Xenograft
Chemical Information
-
Molecular Weight 462.34
-
Formula C24H20BrN3O2
-
SMILES
O=C(NO)/C=C/C1=CC=C(CN2C(C3=CC=C(Br)C=C3)=NC4=CC(C)=CC=C24)C=C1
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)